Q2 EPS Estimates for AstraZeneca Boosted by Zacks Research

Key Points

• Analysts at Zacks Research have raised their Q2 2026 EPS estimate for AstraZeneca to $1.23, reflecting a slight increase from the previous estimate of $1.22.
• Berenberg Bank has set a price target of $97.00 for AstraZeneca, with analysts assigning a consensus rating of "Moderate Buy" and an average price target of $86.00.
• AstraZeneca reported a revenue increase of 16.1% year-over-year for Q2, with earnings per share hitting the consensus estimate of $1.09.

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Equities research analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, September 11th. Zacks Research analyst Team now anticipates that the company will post earnings of $1.23 per share for the quarter, up from their previous estimate of $1.22. The consensus estimate for AstraZeneca's current full-year earnings is $4.51 per share. Zacks Research also issued estimates for AstraZeneca's FY2026 earnings at $5.03 EPS, Q1 2027 earnings at $1.28 EPS, Q2 2027 earnings at $1.39 EPS and FY2027 earnings at $5.70 EPS.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting analysts' consensus estimates of $1.09. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company's quarterly revenue was up 16.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.24 earnings per share.

Separately, Berenberg Bank set a $97.00 price objective on AstraZeneca in a research note on Wednesday, July 9th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $86.00.

AstraZeneca Stock Performance

AZN traded down $1.51 during trading on Friday, hitting $78.05. The stock had a trading volume of 4,447,078 shares, compared to its average volume of 3,152,828. The firm has a market cap of $242.06 billion, a PE ratio of 18.00, a P/E/G ratio of 1.46 and a beta of 0.37. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. AstraZeneca has a 12 month low of $61.24 and a 12 month high of $82.41. The company has a 50 day simple moving average of $75.95 and a 200-day simple moving average of $72.93.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were given a $0.505 dividend. The ex-dividend date was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca's dividend payout ratio (DPR) is currently 37.97%.

Institutional Investors Weigh In On AstraZeneca

Institutional investors have recently bought and sold shares of the business. Lindbrook Capital LLC increased its holdings in shares of AstraZeneca by 1.9% in the first quarter. Lindbrook Capital LLC now owns 7,574 shares of the company's stock valued at $557,000 after purchasing an additional 141 shares during the last quarter. Principal Securities Inc. grew its holdings in AstraZeneca by 0.5% in the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock valued at $2,062,000 after buying an additional 142 shares in the last quarter. Sage Mountain Advisors LLC increased its stake in shares of AstraZeneca by 3.4% in the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company's stock worth $329,000 after acquiring an additional 147 shares during the last quarter. Pekin Hardy Strauss Inc. raised its holdings in shares of AstraZeneca by 4.2% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company's stock worth $255,000 after acquiring an additional 148 shares during the period. Finally, Richardson Financial Services Inc. boosted its position in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company's stock valued at $28,000 after acquiring an additional 149 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.